rinucumab rinucumab rinucumab (regn2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration. rinucumabmonoclonal antibodytype?sourcehumantargetplatelet-derived growth factor receptor betaclinical dataother namesregn2176atc codenoneidentifierscas number1569263-06-4chemspidernoneunii10e3o6yi4wchemical and physical dataformulac6472h9974n1710o2022s38molar mass145309.21 g·mol−1 this drug was developed by regeneron pharmaceuticals, inc.